$31.095
+1.894 (+6.09%)終値時点
IRLA の同業比較
In the context of the broader market, IRLA competes directly with industry leaders such as ALDX and IMMP. With a market capitalization of $31.72M, it holds a significant position in the sector. When comparing efficiency, IRLA's gross margin of N/A stands against ALDX's N/A and IMMP's 100.00%. Such benchmarking helps identify whether IRulya Therapeutics Inc is trading at a premium or discount relative to its financial performance.
IRulya Therapeutics Inc. の財務パフォーマンス
The company has shown consistent net income losses, with a projected loss of -75,488,000 for Q2 2026. Its gross profit has been negligible, and the current ratio has declined significantly, indicating potential liquidity problems.
Financials
FY2026Q2
0.00
Total Revenue
FY2026Q2
YoY:
+114.52%
-21.23M
Operating Profit
FY2026Q2
YoY:
+370.36%
-75.49M
Net Income after Tax
FY2026Q2
YoY:
-82.09%
-12.31
EPS - Diluted
FY2026Q2
YoY:
+63.65%
-18.89M
Free Cash Flow
関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。